German independent biomedical research institute BioMed X has launched a new collaboration with Japanese drugmaker Daiichi Sankyo (TYO: 4568).
This collaboration marks the start of a cutting-edge initiative to explore innovative approaches in cancer treatment using multi-specific biologics. The new project, titled New Strategies for Targeting of Solid Tumors with Multi-Specific Biologics (MTT; Multi-Specific Targeting of Tumor s), will be hosted at the BioMed X Institute in Heidelberg.
The goal of this partnership is to leverage the latest advances in multi-functional biologics, such as bi- and tri-specific antibodies, to develop new therapies that can engage multiple targets simultaneously within the tumor microenvironment. These next-generation therapies aim to overcome the limitations of conventional treatments by leveraging synergistic effects of different antitumor signaling pathways and mechanisms by manipulating proximity of multiple targets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze